Author:
de Souza Paul L.,Liauw Winston,Links Matthew,Pirabhahar Saiyini,Kelly Graham,Howes Laurence G.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference19 articles.
1. Aguero MF, Facchinetti MM, Shelg Z, Senderowicz AM (2005) Phenoxodiol, a novel isoflavone, induces G1 arrest by specific loss in cyclin—dependent kinase 2 activity by p53-independent induction of p21WAF1/CIP1. Cancer Res 65:3364–3373
2. Carpenter TO, Gerloczy A, Pitha J (1995) Safety of parenteral hydroxypropyl beta-cyclodextrin. J Pharm Sci 84:222–225
3. Carraway H, Hidalgo M (2004) New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res 6:219–224
4. Constantinou AI, Husband A (2002) Phenoxodiol (2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl)), a novel isoflavone derivative, inhibits DNA topoisomerase II by stabilizing the cleavable complex. Anticancer Res 22:2581–2585
5. Irie T, Fukunaga K, Garwood MK, Carpenter TO, Pitha J (1992) Hydroxypropylcyclodextrins in parenteral use. II: effects on transport and disposition of lipids in rabbit and humans. J Pharm Sci 81:524–528
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献